Mostrar el registro sencillo

dc.contributor.authorSan Segundo, Davides_ES
dc.contributor.authorGuiral Foz, Sandra A.es_ES
dc.contributor.authorBenito Hernández, Adalbertoes_ES
dc.contributor.authorRenaldo Fernández, Andrées_ES
dc.contributor.authorArnau Prieto, Álvaroes_ES
dc.contributor.authorValero, Rosalíaes_ES
dc.contributor.authorRamos Barrón, María Angeleses_ES
dc.contributor.authorGarcía Unzueta, María Teresa es_ES
dc.contributor.authorGómez Ortega, José Maríaes_ES
dc.contributor.authorLópez Hoyos, Marcos es_ES
dc.contributor.authorRuiz, Juan Carloses_ES
dc.contributor.authorRodrigo Calabia, Emilio es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-04-27T18:23:48Z
dc.date.available2022-04-27T18:23:48Z
dc.date.issued2022-02es_ES
dc.identifier.issn0966-3274es_ES
dc.identifier.issn1878-5492es_ES
dc.identifier.urihttp://hdl.handle.net/10902/24636
dc.description.abstractBackground: Urinary CXCL10 (uCXCL10) is associated with graft inflammation and graft survival, but the factors related to its excretion are not well known. HLA molecular matching at epitope level allow estimating the "dissimilarity" between donor and recipient HLA more precisely, being better related to further transplant outcomes. The relationship between uCXCL10 and HLA molecular mismatch has not been previously explored. Methods: HLA class I and class II typing of some 65 recipients and their donors was retrospectively performed by high resolution sequence-specific-primer (Life Technologies, Brown Deer, WI). The HLA-Matchmaker 3.1 software was used to assess eplet matching. Urine samples collected on the day of the 1-year surveillance biopsy were available of these 65 patients. uCXCL10 was measured using a commercial enzyme-linked immunoassay kit. Results: 1-year uCXCL10 was independently associated with HLA-DQB1 eplet mismatch load (b 0.300, 95%CI 0.010-0.058, p = 0.006). Kidney transplant recipients with a HLA-DQB1 eplet mismatch load >3 showed higher values of uCXCL10 at 1-year (p = 0.018) than those with < = 3. Patients with a HLA-DQB1 eplet mismatch load >3 with subclinical AbMR had significantly higher levels of the logarithm of 1-year uCXCL10 (No AbMR 0.88, IQR 0.37; AbMR 1.38, IQR 0.34, p = 0.002) than those without AbMR. Conclusions: uCXCL10 specifically relates to HLA-DQ eplet mismatch load. This relationship can partly explain the previously reported association between uCXCL10 excretion and graft inflammation. An adequate evaluation of any potential non-invasive biomarker, such as uCXCL10, must take into account the HLA molecular mismatch.es_ES
dc.description.sponsorshipThis research was funded by grants for Fondo de Investigaciones Sanitarias-ISCIII (PI14/00378, PI16/01585, PI20/01710), RedinRen (RD16/0009/0027), and Instituto de Investigación Marqués de Valdecilla (IDIVAL, TRANSVAL18/01).es_ES
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceTransplant Immunology, Volume 70, February 2022, 101494es_ES
dc.subject.otherAntibody mediated rejectiones_ES
dc.subject.otherBiomarkerses_ES
dc.subject.otherCellular rejectiones_ES
dc.subject.otherCXCL10es_ES
dc.subject.otherKidney transplantationes_ES
dc.subject.otherHLA molecular mismatches_ES
dc.titleUrinary CXCL10 specifically relates to HLA-DQ eplet mismatch load in kidney transplant recipientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.trim.2021.101494es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.trim.2021.101494es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International